Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

NCT03020030 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT03020030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03020030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 3, 2017
Completion date
November 30, 2034
Enrollment
560 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, pediatric